



Received on 15 October, 2016; received in revised form, 13 December, 2016; accepted, 16 December, 2016; published 01 May, 2017

DEVELOPMENT OF ONDANSETRON HCL FAST DISINTEGRATING TABLETS USING 3² FULL FACTORIAL DESIGN

S. M. Shahidulla ^{*1}, Mohib Khan ² and K. N. Jayaveera ³

Department of Pharmaceutics ¹, Deccan School of Pharmacy, Hyderabad - 500001, Telangana, India.

Department of Pharmaceutics ², Oriental College of Pharmacy, Mumbai - 400705, Maharashtra, India.

Jawaharlal Nehru Technological University ³, Anantapur - 515001 Andhra Pradesh, India.

Keywords:

Ondansetron HCl, Fast Disintegrating Tablets, *Plantago ovata* mucilage, *Ocimum basilicum* mucilage, 3² Full Factorial Design

Correspondence to Author:

S. M. Shahidulla

Deccan School of Pharmacy,
Dar-us-salam, Aghapura,
Hyderabad - 500001,
Telangana, India.


E-mail: s.shahidulla@gmail.com

ABSTRACT: The present investigation was carried out to study the disintegrant property of *Plantago ovata* and *Ocimum basilicum* mucilages. The objective of the work was to develop Fast disintegrating tablets of Ondansetron HCl with a view to enhance patient compliances and dissolution rate by direct compression method using 3² full factorial design. *Plantago ovata* (2-10% w/w), *Ocimum basilicum* (4-8% w/w) mucilages were used as natural superdisintegrant and microcrystalline cellulose was used as diluent, along with directly compressible mannitol to enhance mouth feel. The tablets were evaluated for hardness, friability, thickness, drug content uniformity, in vitro dispersion time, wetting time and water absorption ratio. Based on in vitro dispersion time (approximately 11 s); the formulation containing 10% w/w *Plantago ovata* and 8% *Ocimum basilicum* mucilages were found to be promising and tested for in vitro drug release pattern (in 0.1 N HCl), short-term stability (at 40°/75 % RH for 6 mo) and drug-excipient interaction. Surface response plots are presented to graphically represent the effect of independent variables (concentrations of *Plantago ovata* and *Ocimum basilicum* mucilages) on the in vitro dispersion time. The validity of the generated mathematical model was tested by preparing two extra-design check point formulations. The optimized tablet formulation was compared with conventional commercial tablet formulation for drug release profiles. This formulation showed two-fold faster drug release (t_{50%} 3.6 min) compared to the conventional commercial tablet formulation (t_{50%} 7 min). Short-term stability studies on the formulation indicated that there are no significant changes in drug content and in vitro dispersion time (p < 0.05).

INTRODUCTION: Mucilage is most commonly used as excipients in the manufacturing of different pharmaceutical dosage forms. They have a variety of pharmaceutical properties, which include binding, disintegrating, suspending, emulsifying and sustaining properties at different proportion in different pharmaceutical dosage forms ¹⁻⁴.

Natural mucilages are preferred over semi-synthetic and synthetic materials due to their non-toxic, low cost, free availability, emollient and non-irritating nature ⁵⁻⁶.

Fast disintegrating tablet system can be defined as a tablet that disintegrates and dissolves rapidly in saliva without need of drinking water ⁷. In spite of tremendous development in drug delivery technology, oral route remains perfect route for administration of because of low cost of therapy, ease of administration, accurate dose, self medication, pain avoidance, leading to high level of patient compliance. Tablets and capsules are the most popular dosage forms ⁸ but main drawback of such dosage forms is dysphasia or difficulty in

QUICK RESPONSE CODE	DOI: 10.13040/IJPSR.0975-8232.8(5). 2143-48
	Article can be accessed online on: www.ijpsr.com
DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.8(5). 2143-48	

swallowing. This problem led to development of novel solid dosage forms such as Fast disintegrating tablets that disintegrate and dissolve rapidly in saliva without need of water. Fast disintegrating tablets avoid first pass metabolism and enhance bioavailability of active ingredient⁹.

Ondansetron HCl is a potent highly selective antagonist at the 5 HT₃. It is a carbazole which causes anti nauseant and anti emetic effects by selective and comperative blockade of the 5 HT₃ receptors¹⁰. The aim was to develop Ondansetron HCl fast disintegrating tablets using 3² full factorial design with enhanced bioavailability.

MATERIALS AND METHODS: Ondansetron HCl was obtained as gift sample from Arabindo Pharmaceuticals Pvt Ltd, Hyderabad. The seeds of *Plantago ovata* and *Ocimum basilicum* were purchased from the local market of Ongole, Andhra Pradesh. Directly compressible mannitol (Pearlitol SD200), sodium stearyl fumarate and microcrystalline cellulose (Avicel PH-102) were generous gifts from Strides Arco Labs, Bangalore, Glenmark Ltd., Nashik and Alkem Labs Pvt Ltd, Mumbai, India. All other chemicals used were of analytical reagent grade.

Isolation of mucilage: For the isolation of mucilage¹¹, seeds of *Plantago ovata* were used. They were soaked in distilled water for 48 hours and then boiled for 1 hr for complete release of mucilage into water. The material collected was squeezed through muslin cloth for filtering and separating out the marc. Then, an equal volume of

acetone was added to the filtrate so as to precipitate the mucilage. The separated mucilage was dried (in oven at temperature less than 60⁰ C), powdered, sieved (#60) and stored in a desiccator until further use.

Isolation of *Ocimum basilicum* Mucilage: Basil seeds were rinsed with water to remove foreign particles. Seeds were soaked in water (seed: water= 1:10) for 20 minutes. The swollen seeds subjected to high agitation using homogenizer at 1500 rpm to separate gel layer from seeds¹². The separated gel layer was passed through muslin cloth to remove unwanted particles and then precipitated using acetone. The precipitate was washed with ethanol and dried in hot air oven at 40⁰C. The dried mucilage was powdered and stored in airtight container.

Preparation of Fast disintegrating tablets of Ondansetron HCl by direct compression method: Fast disintegrating tablets of Ondansetron HCl were prepared by direct compression method¹³. According to the formulae given in **Table 1**. All the ingredients were passed through #60 mesh separately. The drug and MCC were mixed by taking small portion of both each time and blending it to get a uniform mixture and kept aside. Then the other ingredients were weighed and mixed in geometrical order and tablets were compressed using 6 mm round flat punches to get tablets of 100 mg weight on a 10-station rotary tablet machine (Clit, Ahmedabad).

TABLE 1: FACTORIAL DESIGN FORMULATIONS OF ONDANSETRON HCl PREPARED BY DIRECT COMPRESSION METHOD

Ingredients (mg/tablet)	Formulation code											
	OD F ₀	OD F ₁	OD F ₂	OD F ₃	OD F ₄	OD F ₅	OD F ₆	OD F ₇	OD F ₈	OD F ₉	C ₁	C ₂
Ondansetron HCl	4	4	4	4	4	4	4	4	4	4	4	4
<i>Plantago ovate</i> mucilage	---	2	2	2	6	6	6	10	10	10	4	8
<i>Ocimum basilicum</i> mucilage	---	4	6	8	4	6	8	4	6	8	5	7
MCC	10	0	15	30	0	15	30	0	15	30	7.5	22.5
Aspartame	3	3	3	3	3	3	3	3	3	3	3	3
Sodium stearyl fumarate	2	2	2	2	2	2	2	2	2	2	2	2
Talc	2	2	2	2	2	2	2	2	2	2	2	2
Banana flavour	1	1	1	1	1	1	1	1	1	1	1	1
Mannitol SD-200	78	82	65	48	78	61	44	74	57	40	71.5	50.5
Total	100	100	100	100	100	100	100	100	100	100	100	100

Formulation ODF₉ was selected as the best and used in further studies;

ODF₀ control formulation, C₁ and C₂ are extra design check-point formulation

Evaluation of Fast Disintegrating Tablets: The prepared Fast disintegrating tablets were evaluated for different parameters like hardness, thickness, friability, weight variation test, drug content, wetting time and water absorption ratio, *in vitro* dispersion time and *in vitro* dissolution test.

Hardness: The crushing strength of tablets was measured by using Monsanto hardness tester¹⁴.

Thickness: Tablet thickness was measured by using Screw gauge. Three tablets were randomly taken, and measured by placing between two arms of Screw gauge.

Weight variation test: Twenty tablets were selected at random and average weight was determined using an electronic balance (Shimadzu BL-220H). Tablets were weighed individually and compared with average weight¹⁵.

Friability test: The friability of tablets was measured in Roche friabilator¹⁶. Twenty tablets were dedusted at 25 rpm for 4 min and weighed again. Percentage friability was calculated from loss in weight as given in equation below. The weight loss should not be more than 1% (**Table 2**).

% Friability = [(Initial weight - Final weight)/Initial weight]×100.

TABLE 2: EVALUATION OF FACTORIAL FORMULATIONS

Formulation	Hardness* (kg/cm ²)±SD	Thickness (mm)	Friability (%)	<i>In vitro</i> dispersion time* (sec) ±SD	Drug content* (%)±SD	Wetting time* (seconds) ±SD	Water absorption ratio (%)
ODF ₀	4.2±0.109	3.11	0.54	170±1.22	99.1±0.5	172.1±1.5	48.1
ODF ₁	4.1±0.189	3.03	0.66	47.94±0.73	96.72±0.48	51.89±0.67	63.75
ODF ₂	4.07±0.131	3.1	0.59	40.77±0.65	95.17±0.92	42.27±0.37	67.96
ODF ₃	4.04±0.06	3.05	0.72	26.38±0.54	99.52±0.45	27.91±0.11	73.05
ODF ₄	4.12±0.104	2.87	0.83	40.08±0.18	100.16±1.0	41.24±0.26	69.47
ODF ₅	4.03±0.068	3.15	0.51	33.99±0.176	97.02±0.12	36.32±0.39	74.25
ODF ₆	4.25±0.05	3.29	0.48	20.05±0.1	104.78±0.48	19.97±0.11	77.1
ODF ₇	4.14±0.1	3.26	0.61	31.98±0.18	97.16±0.42	34.19±0.22	76.3
ODF ₈	4.37±0.064	2.94	0.79	21.06±1.63	104.74±0.51	22.81±0.25	80.14
ODF ₉	4.15±0.06	3.03	0.85	11.07±0.13	100.1±0.11	13.05±0.14	84.19
C ₁	4.30±0.10	2.9	0.48	34.17±0.86	100.10±0.10	35.27±0.31	73.8
C ₂	4.46±0.057	3.06	0.52	20.81±0.52	99.73±0.73	22.01±0.59	79.94

*Average of three determinations. Weight variation (95-105 mg) within the IP limits of ±10%

TABLE 3: IN VITRO DISSOLUTION PARAMETERS IN 0.1 N HCl

Formulation code	D ₅ (%)	D ₁₀ (%)	DE _{10min} (%)	t _{25%} (min)	t _{50%} (min)	t _{90%} (min)
ODF ₀	29.0	48.5	26.89	4.3	10.5	>12
ODF ₉	60.0	85.7	54.23	1.5	3.6	11.6
CCF	35.00	66.5	34.54	3.5	7.0	>12

ODF₀ is control formulation, ODF₉ is promising fast disintegrating tablet formulation, CCF is conventional commercial tablet formulation, D₅ is percent drug released in 5 min, D₁₀ is percent drug release in 10 min, DE_{10min} is dissolution efficiency at 10 min, t_{25%} is time for 25% drug dissolution, t_{50%} is time for 50% drug dissolution, t_{90%} is time for 90% drug dissolution.

Drug content: A tablet was crushed and dissolved 1 ml of dilute HCl and 30 ml of distilled water¹⁷. This solution was shaken for 15 min, the volume of this solution was made up to 50 ml with distilled water and centrifuged. 5 ml of the clear supernatant was mixed with 10 ml of 0.1 N HCl, and made up to 100 ml with distilled water. The absorption of the solution was determined spectrophotometrically at 249 nm. The same procedure was followed for another nine tablets.

Wetting time and water absorption ratio: For determination of wetting time and water absorption ratio¹⁸, a piece of tissue paper folded twice was placed in a small Petri dish (internal diameter of 5 cm) containing 6 ml of water. A tablet was placed on the paper and the time required for complete wetting was measured. The wetted tablet was then weighed. Water absorption ratio 'R' was calculated using the equation: $R=100 \times (W_a - W_b) / W_a$, where W_a is weight of tablet after water absorption and W_b is weight of tablet before water absorption.

In vitro dispersion time: *In vitro* dispersion time was determined by placing one tablet in a Petri dish containing 10 ml of water and the time required for complete dispersion was determined¹⁹⁻²⁰.

In vitro dissolution test: *In vitro* dissolution studies of the optimized fast disintegrating tablets of Ondansetron HCl and commercial conventional tablet was performed according to USP XXIII Type-II dissolution apparatus (Electrolab, model TDT-06N) employing a paddle stirrer at 50 rpm using 900 ml of 0.1 N HCl at 37±0.5°C as dissolution medium²¹. One tablet was used in each basket. Aliquots of the dissolution medium (5 ml) were withdrawn at specific time intervals (2, 4, 6, 8, 10 and 12 min) and replaced with the equal volume of fresh medium. The samples were analyzed for drug content by measuring the absorbance at 249 nm. Drug concentration was calculated from the standard calibration curve and states cumulative percent drug dissolved.

Drug-excipient interaction study: IR spectra of Ondansetron HCl and its formulations were obtained by KBr pellet method using Perkin-Elmer FTIR series (Model 1615) spectrophotometer in order to ruled out drug-excipients interactions.

Stability testing: Accelerated stability studies on formulation ODF₉ were carried out by storing 15 tablets in an amber coloured rubber stoppered vials at 40o/75% RH over a period of 6 months.

Experimental design: The 3² full factorial design was used for the optimization of Fast disintegrating tablets of Ondansetron HCl (Design Expert 8.0.7.1). The two independent factors, concentration of *Plantago ovata* mucilage (X₁) and concentration of *Ocimum basilicum* mucilage (X₂), were set to three different levels and experimental trials were performed for all nine possible combinations²². The dependent response, *in-vitro* dispersion time (Y₁) was evaluated.

Validation of the experimental design: To validate the experimental design using a polynomial equation, the dependent response, *in-vitro* dispersion time was selected. The following second order polynomial equation was applied as a tool of mathematical modeling²³.

$$Y = b_0 + b_1X_1 + b_2X_2 + b_{12}X_1X_2 + b_{11}X_1^2 + b_{22}X_2^2$$

where, Y is the dependent variable, b₀ is the arithmetic mean response of the nine runs and b₁ (b₁, b₂, b₁₂, b₁₁ and b₂₂) is the estimated coefficient for corresponding factor X₁ (X₁, X₂, X₁₂, X₁₁, and X₂₂), which represents the average results of changing one factor at a time from its low to high value. The interaction term (X₁X₂) describes the changes in the response when two factors are simultaneously changed. The polynomial terms (X₁² and X₂²) are included to investigate nonlinearity.

RESULTS AND DISCUSSION: Fast disintegrating tablets of Ondansetron HCl were prepared by direct compression method using *Plantago ovata* and *Ocimum basilicum* mucilages were natural superdisintegrants and MCC as diluent along with directly compressible mannitol (Pearlitol SD 200), which was used to enhance the mouth feel. A total of nine formulations, a control formulation (ODF₀, without superdisintegrant) and two extra-design check point formulations (C₁ and C₂ to check validity of the developed polynomial equation), were designed.

Powder blends were evaluated for the flow parameters such as angle of repose, tapped density, bulk density and Carr's index. As the material was free flowing (angle of repose values were found to be <30° and Carr's index <15%).

The tablets were evaluated for weight variation, uniformity of drug content, hardness, friability, *in vitro* dispersion time, *in vitro* dissolution studies, tablets obtained were of uniform weight (due to uniform die fill), with acceptable variation as per IP specifications (±10%). Drug content was found to be in the range of 95-105%, which is within acceptable limits. Hardness of the tablets was found to be 4.0 to 4.5 kg/cm². Friability below 1% was an indication of good mechanical resistance of the tablets. Formulation ODF₉ was found to be promising and shown an *in vitro* dispersion time of 11 s, which facilitates faster dispersion in the mouth.

In order to investigate the factors systematically, a factorial design was employed in the present investigation. Formulation has been done by using 3² full factorial design, preparing nine batches of formulations (ODF₁ to ODF₉).

A polynomial equation was derived for *in vitro* dispersion time, by Design Expert 8.0.7.1 software. Formulation ODF₉ containing 10% w/w *Plantago ovata*, 8% w/w *Ocimum basilicum* mucilages were found to be promising with an *in vitro* dispersion time of 11 s against the 170s displayed by control formulation (DF₀), which does not contain the superdisintegrants.

In vitro dissolution studies on the promising formulation (ODF₉), the control (ODF₀) and conventional commercial tablet formulation (CCF) were carried out in 0.1 N HCl and the various dissolution parameter values, viz., percent drug dissolved in 5 min (D₅), 10 min (D₁₀), dissolution efficiency at 10 min (DE_{10min}), t_{25%}, t_{50%} and t_{90%} are shown in Table 3 and the dissolution profile shown in Fig. 1. This data reveals that overall, the formulation ODF₉ has shown two-fold faster drug release (t_{50%} 3.6 min) when compared to CCF (t_{50%} 7min).




FIG. 1: IN VITRO CUMULATIVE PERCENT DRUG RELEASE VERSUS TIME PROFILE OF PROMISING ONDANSETRON HCL FORMULATIONS Plot showing cumulative percent drug release in 0.1 N HCl from control formulations (◆-); promising ODF₉ formulation (■-); conventional commercial tablet formulation CCF (▲-).

IR studies indicated that the drug is compatible with all the excipients. The IR spectrum of ODF₉ shown all the characteristic peaks of Ondansetron HCl, thus confirming that no interaction of drug with the components of the formulation. Short-term stability studies of the above formulation indicated that there are no significant changes in drug content and *in vitro* dispersion time at the end of 6 months period ($P < 0.05$).

The equation derived for *in vitro* dispersion time of the factorial formulations is, $Y_1 = 30.36 - 10.41 X_1 - 8.49 X_2$. The negative sign for coefficients of X_1 and X_2 indicate that as the concentration of disintegrants increases, *in vitro* dispersion time decreases. Validity of this equation was verified by designing two extra design check point formulations (C₁ and C₂) and determining the *in vitro* dispersion time. The *in vitro* dispersion time values predicted from the equation for these formulations are 37.21 and 16.5 sec, where as those observed from experimental results are 39.76 and 20.96 sec, respectively. The closeness of the predicted and observed values for C₁ and C₂ in the method indicates validity of derived equation for the dependent variable (*in vitro* dispersion time). The computer generated response surface and contour plots for the dependent variable are shown in Fig. 2 and 3, respectively.




FIG. 2: RESPONSE SURFACE PLOT OF FACTORIAL VARIABLES ON IN VITRO DISPERSION TIME




FIG. 3: CONTOUR PLOT OF FACTORIAL VARIABLES ON IN VITRO DISPERSION TIME

CONCLUSION: A 3^2 full factorial design revealed that the amounts of *Plantago ovata* mucilage (X_1) and *Ocimum basilicum* mucilage (X_2) significantly affect the dependent variable (Y_1), the *in vitro* dispersion time. It is thus concluded that, by adopting a systematic formulation approach, an optimum point can be reached in the shortest time with minimum efforts. Direct compression method by using natural superdisintegrants would be an effective approach compared with the use of more expensive excipients in the formulation of fast disintegrating tablets with smaller disintegration time, improved drug dissolution, patient compliance, convenience and acceptability.

ACKNOWLEDGEMENTS: The authors are thankful to Arabindho Pharmaceutical Pvt Ltd, Hyderabad for providing gift sample of Ondansetron HCl. They also wish to express their gratefulness to the Principal, Deccan School of Pharmacy, Hyderabad for providing the necessary facilities for the study.

REFERENCES:

- Baveja SK, Gupta BM. Rheology of Aqueous dispersions of *Plantago ovata* seed husk-I. Indian J Pharm Sci 1968;30:187-94.
- Baveja SK, Gupta BM. Rheology of Aqueous dispersions of *Plantago ovata* seed husk-II. Indian J Pharm Sci 1968; 30:247-51.
- Pradeep SP, Suneel K. Formulation and evaluation of oro dispersible tablets of perindopril erbumine using natural superdisintegrant. J drug deli and therapeutics 2013; 3 (5): 44-48.
- Sai padmini B, Syamala S. Formulation and evaluation of oro dispersible tablets of Clonazepam using natural superdisintegrant. J pharm and bio sci 2014; 4 (1): 47-52.
- Kulkarni GT, Gowthamarajan K and Rao BG. Suresh B. Evaluation of binding property of *Plantago ovata* and *Trigonella Foenum graecum* mucilage. Indian Drugs 2002; 39:422-5.
- Washi SP, Sharma VD and Sinha P. *Plantago ovata*: genetic diversity, cultivation, utilization and chemistry. Indian J Nat Prod 1985; 1:3-6.
- Shiv Shankar H and Darwhekar G N. Development and optimization of fast dissolving tablets of promethazine theoclate using 3^2 full factorial design. Int j pharm scin and res 2016; 7 (6): 2499-2509.
- Chein. YW. Oral Drug Delivery and Delivery System. 2nd ed 1992; New York: Marcel Dekker.
- Kuchekar BS, Arumugam V. Fast dissolving tablets. Indian J Pharm Edu 2001; 35:150-2.
- Sweetman SC, Editor. Martindale: The complete drug reference. 33rd Ed 2002; Pharmaceutical press, London, 1235-37 and 1240-43.
- Bavega SK, Rao KV and Arora J. Examination of natural gums and mucilages as sustaining materials in tablet dosage forms-II. Indian J Pharm Sci 1989; 51:115-8.
- Sunitha reddy M, Sri vidyalalitha T. Formulation and evaluation of fast disintegrating tablets of lamivudine using ocimum basilicum seed mucilage as superdisintegrant. World j pharm res 2014; 3 (10): 1292-1304.
- Shirsand SB, Sarasija Suresh. *Plantago ovata* mucilage in the design of Fast disintegrating tablets. Indian J Pharm Sci 2009; 71(1):41-45.
- Devendre RR, Vikas VP. Formulation and evaluation of fast dissolving tablet of albendazole. Int Current Pharm J 2012; 1(10):311-16.
- Banker GS, Anderson GR. Tablets. In: Lachman L, Liberman HA, Kanig JL, editors. The theory and practice of industrial pharmacy. 3rd ed 1987; Mumbai: Varghese Publishing House. 293-9.
- Lachman L, Lieberman A and Kinig JL. The Theory and Practice of Industrial Pharmacy. Varghese Publishing House 1991; 67-68.
- Indian Pharmacopoeia, 4th Ed 1996; vol-II: Controller of publications. Government of India, ministry of health and family welfare, New Delhi: 735.
- Tawfeek H M, Jelan A, and Mahmoud M A. development and optimization of itopride HCl fast disintegrating tablets using factorial design and response surface methodology. Int j pharm sci and res 2015; 6(4): 1661-72.
- Nilesh J, Suman M. Effect of superdisintegrants on formulation of taste masked fast disintegrating ciprofloxacin tablets. Int Current Pharm J 2012; 1(4):62-67.
- Gohel M, Patel M and Bariya N. Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique. AAPS PharmSciTech 2004; 5(3):10-15.
- Subhashini R and Ramesh Reddy D. Formulation and evaluation of Domperidone fast dissolving tablets using *Plantago ovata* mucilage. Int J Pharm Scien and res 2013; 4(9):3489-93.
- Bolton S. Pharmaceutical Statistics. 2nd ed 1990; New York: Marcel Decker Inc. 234-6.
- Singh J, Philip AK and Pathak K. Optimization studies on design and evaluation of oro dispersible pediatric formulation of indomethacin. AAPS Pharm Sci Tech 2008; 9:60-66.

How to cite this article:

Shahidulla SM, Khan M and Jayaveera KN: Development of ondansetron HCl fast disintegrating tablets using 3^2 full factorial design. Int J Pharm Sci Res 2017; 8(5): 2143-48.doi: 10.13040/IJPSR.0975-8232.8(5).2143-48.

All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to **ANDROID OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)